SEC Filing Summary

Stephen D. Griffin, President and CEO of Anika Therapeutics, Inc., reported transactions on March 14, 2026. He acquired 12,824 shares of Common Stock through the vesting of Restricted Stock Units (RSUs) with a reported price of $0.00. Additionally, 6,412 performance-based phantom RSUs (PSUs) vested, also valued at $0.00 per share. In a separate transaction, 5,944 shares were disposed of to cover tax withholding obligations related to RSUs and PSUs, at a price of $14.20 per share. Following these transactions, Griffin holds 23,963 shares of common stock directly. The reporting owner is a director and officer of the company. The filing is a Form 4, indicating changes in beneficial ownership.